Hematologic Oncology Update

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:
Introduction (0:00)
The Biopathophysiology of Myelofibrosis (MF) (2:19)
Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)
Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)
Upcoming at European Hematology Association (EHA) 2026 (49:22)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:
Introduction (0:00)
Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
Introduction (00:00)
Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
Utility of Belantamab Mafodotin in R/R MM (49:29)
Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman, including the following topics:
The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
Zanubrutinib-based therapy for treatment-naïve CLL (12:32)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)

CME information and select publications